STIFEL 2026 HEALTHCARE CONFERENCE - ABCELLERA BIOLOGICS INC

Explicit Guidance:

• No specific financial guidance: The transcript contains no explicit revenue, earnings, margin, capex, or cash flow guidance for any period.
• Future Revenue Potential: Management states that following the Phase 2 data, the commercial potential for ABCL-635 is expected to be "multiples" of a "blockbuster product," contrasting with prior estimates where the product was already viewed as a potential blockbuster.
• Commercial Pricing Strategy: Anticipates pricing ABCL-635 above the current net price of small molecule competitors (approx. $5,000/year) to reflect superior efficacy, safety, and convenience, with pricing balances considered for U.S. versus ex-U.S. markets.

Business-Segment Outlook:

• ABCL-635 (Menopause/VMS):
  • Development Timeline: Phase 3 studies expected to initiate "next year" (2025).
  • Readout Timeline: Projected Phase 3 readout roughly two and a half years from first patient in (approx. late 2027), benchmarked against competitor timelines (Linquist/Vioza).
  • Dosing Regimen: Anticipated induction/maintenance model (600mg loading dose followed by 300mg once-monthly maintenance), fitting a 2mL auto-injector; lower doses or less frequent dosing remain possibilities pending Phase 2 Open Label Extension (OLE) data.
  • Market Share: Targets a "big chunk" of the non-hormonal market, potentially capturing patients currently on hormone therapy due to safety/efficacy advantages, and those who previously avoided treatment due to contraindications or intolerance.
• Oncology Pipeline:
  • Indications: Prostate cancer and breast cancer studies planned for "next year" (2025).
  • Strategy: Early-stage studies serve as proof-of-concept before broader development.
• Platform Expansion:
  • ABCL-992: Half-life extended version of ABCL-635 (potential 3-month dosing interval) to reduce cost of goods and increase supply.
  • ABCL-688 & ABCL-386: Currently in Investigational New Drug (IND)-enabling studies; projected to enter the clinic "next year."
  • New Candidates: Two additional undisclosed programs (ABCL-385, a first-in-class ion channel antagonist; and ABCL-646) expected to enter the clinic over the next 12–24 months.
  • Pipeline Cadence: Strategy aims to bring one or two new development candidates forward annually.

Market and Competitive Outlook:

• Competitive Landscape: ABCL-635 positioned to outperform small molecule competitors (fezolinetant, elenzanitant) on efficacy (50% placebo-controlled reduction vs. ~25-30% for small molecules), safety (no liver toxicity risk), and convenience (once-monthly).
• Share Gains: Potential to capture significant market share from current small molecules and hormone therapies, driven by the "unprecedented" 37% complete resolution rate seen at week 4 and superior sleep score improvements without NK1R-associated somnolence.
• Commercialization Model: Anticipates a shift away from traditional 1,500+ sales rep models toward technology-enabled Direct-to-Consumer (DTC) channels, telehealth, and virtual clinics, similar to the GLP-1 trend in obesity medicine.
• Market Expansion: Potential to expand the addressable market by targeting patients ineligible for or refusing hormone therapy, including those facing hormone supply shortages.

Macro / Industry Outlook:

• Hormone Supply Shortages: Cites current shortages in estrogen patches (driven by FDA guideline changes) as a tailwind, pushing patients toward non-hormonal alternatives.
• Prescribing Trends: Observes a shift from OBGYNs to Primary Care Physicians (GPs) and an increase in patient-controlled, direct-to-consumer prescribing models.
• Regulatory Environment: Admitted to the FDA's Model-Informed Drug Development (MIDD) program to facilitate Phase 3 dosing selection without extensive empirical Phase 2 dose-ranging.
• Long-term Therapy: Anticipates long-duration treatment, citing a median hot flash duration of ~7 years, with a subset of patients (10–20%) requiring treatment for 10+ years.

Strategic Initiatives:

• Next-Generation Product Development: Accelerating development of half-life extended analogs (e.g., ABCL-992) to secure commercial advantage via lower COGs and improved supply, without diverting focus from ABCL-635.
• Commercial Readiness: Parallel work underway on CMC (Chemistry, Manufacturing, and Controls) and device development to support Phase 3 initiation.
• Phase 3 Design: Planning for a global trial (US, Canada, Australia, Europe) with a safety database size of ~1,500 patients (potentially smaller than competitors due to mechanism-specific safety profile), with recruitment not expected to be a limiter.
• Pricing & Access: Evaluating direct pay and insurance provider models for DTC distribution; balancing pricing for global access.

Risks and Headwinds to Outlook:

• Data Validation Risk: The "killer product" status and Phase 3 trajectory rely on the maintenance of Phase 2 efficacy results; however, management notes that Phase 2 data is based on a single dose and steady-state washout, with full persistence data pending the OLE readout expected "early next year."
• Regulatory Uncertainty: While optimistic about the MIDD program, final Phase 3 dosing alignment with the FDA and other regulatory bodies is pending post-Phase 2 meetings.
• Screening Failure: Historically high screen failure rates (75% initially, improved to 65%) due to patient reporting accuracy and compliance adherence could impact enrollment speed, though management expects these to be manageable.
• Competitive Response: The entry of competitors with half-life extended analogs creates a need for rapid development of ABCL-992 to maintain market leadership.

Management Tone on the Future:

• Confidence Level: Highly confident and optimistic; management describes the Phase 2 results as exceeding the "upside scenario" and characterizes the product as "dynamite" and a "killer product" that could "redefine" non-hormonal care.
• Strategic Clarity: Clear intent to capitalize on the data breakthrough with simultaneous pursuit of ABCL-635 and next-generation assets, viewing the pipeline expansion as "building the iceberg."
• Commercial Vision: Enthusiastic about the shift to DTC/telehealth models, viewing them as an opportunity for smaller biotechs to compete effectively against large pharma's traditional sales force structures.

Miscellaneous:

• OLE Data: Open Label Extension data is expected to be shared "early next year," providing three times the efficacy data from the initial Phase 2 cohort.
• Safety Signal: Management anticipates that the NK3R-only mechanism may result in a lower liver toxicity risk compared to dual-acting small molecules, potentially allowing for a more efficient Phase 3 safety database.